Healthcare >> Analyst Interviews >> October 19, 2009
Development In Biotech – Matthew L. Kaplan – Ladenburg Thalmann
MATTHEW L. KAPLAN is Managing Director, Health Care Group - Equity Research, at Ladenburg Thalmann. He focuses on therapeutic companies, cardiovascular and drug delivery. Mr. Kaplan spent 13 years as a Biotechnology Analyst at PZ & Co., Evolution Capital and The Carson Group. He has six years of research experience with the Albert Einstein College of Medicine/Montefiore Hospital Department of Cardiology and has co-authored numerous articles on gene regulation in the heart. Mr. Kaplan holds a B.S. in biology from the University of Michigan. Profile
TWST: Please tell us about your company, Ladenburg Thalmann.
Mr. Kaplan: Ladenburg Thalmann is an investment bank. About a year ago in May, Ladenburg Thalmann acquired a company called Punk Ziegel.